Experience the Power of Ketamine Infusion Therapy for Depression
Ketamine infusion therapy has shown remarkable results in improving the lives of individuals struggling with mental health disorders. Our expertly trained professionals administer personalized treatments that are tailored to each patient’s unique needs, providing them with a renewed sense of hope and well-being.
Anew Era is proud to now offer ketamine infusion therapy to our patients. Esketamine (Spravato®) is a nasal spray that is used to treat depression. It is the first and only FDA-approved nasal spray for adults with two forms of challenging-to-treat major depressive disorder (MDD):
- Adults with treatment-resistant depression (TRD)
- Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.
Esketamine works by blocking the NMDA receptor, which is a type of receptor in the brain that is involved in mood regulation.
Depression and Esketamine
Depression can be debilitating and challenging to treat, especially when traditional therapies have not been effective. Esketamine offers new hope for those suffering from treatment-resistant depression. By targeting the N-methyl-D-aspartate (NMDA) receptors in the brain, esketamine helps regulate mood and emotions, leading to a more balanced mental state.
- 75% of patients who received esketamine (Spravato) experienced a clinical response, and 36.6% experienced remission (Spravato, 2023).
Treating Depression and Other Mental Health Issues
Beyond depression, Spravato and ketamine infusion therapy has shown promise in treating various other mental health issues such as:
- Post-traumatic stress disorder (PTSD)
- Generalized anxiety disorder (GAD)
- Obsessive-compulsive disorder (OCD)
Its versatility and potential to address different conditions make it a valuable option in the world of mental health treatments.
Why Choose Esketamine?
Esketamine stands out as a treatment option due to its rapid onset of action, often providing relief within hours or days, unlike traditional antidepressants that may take weeks to show results. Moreover, it is well-tolerated, and side effects are generally mild and transient. Compared to other treatments, esketamine offers a unique advantage in tackling treatment-resistant depression, providing new avenues for those who have not responded to other therapies.
The History of Ketamine
Ketamine, the parent compound of esketamine in Spravato, was initially developed as an anesthetic in the 1960s. Over time, researchers discovered its powerful antidepressant effects, leading to the exploration of its potential in treating mental health conditions. The development of Spravato marked a significant milestone in harnessing the therapeutic benefits of ketamine for patients with treatment-resistant depression.
Frequently Asked Questions (FAQs)
1. How is esketamine administered?
Esketamine is administered as a nasal spray under the supervision of a healthcare professional.
2. Who is a suitable candidate for esketamine treatment?
Esketamine is generally prescribed to adults who have not responded adequately to at least two different antidepressant treatments. Your healthcare provider will evaluate your specific condition and medical history to determine if esketamine is an appropriate option for you.
3. How long does an esketamine session last?
A typical esketamine session may last around 2 hours, including preparation and observation periods.
4. What can I expect during an esketamine treatment session?
A typical esketamine session involves administering the nasal spray followed by a period of observation to monitor your response and ensure your safety. The healthcare team will be with you throughout the session to address any concerns.
5. How often will I need to receive esketamine treatments?
The frequency of esketamine treatments may vary based on individual response and treatment goals. Initially, you may receive treatments more frequently, and the schedule may be adjusted as you progress.
6. Is esketamine safe?
Esketamine has undergone rigorous testing and received FDA approval. However, like any medication, it may have side effects, some common side effects may include dizziness, nausea, dissociation, and headache.
7. Is esketamine covered by insurance?
Insurance coverage for esketamine may vary, but many insurance plans now cover this treatment. We recommend contacting your insurance provider to understand your specific coverage.
8. Can I drive after receiving esketamine?
You will not be allowed to drive on the day of the treatment, as esketamine may cause drowsiness and impair your ability to operate a vehicle.
9. Is esketamine addictive?
Esketamine is not considered addictive when used as prescribed. It is essential to follow your healthcare provider’s instructions and not exceed the recommended dosage.
10. Can esketamine be used alongside other antidepressant medications?
In some cases, Spravato may be used in combination with other antidepressant medications. However, it is crucial to inform your healthcare provider about any medications you are currently taking to avoid potential drug interactions.
11. Are there any long-term effects of Spravato treatment?
The long-term effects of Spravato are still being studied. However, research thus far has shown it to be effective and generally well-tolerated over time.
12. How quickly can I expect to see improvements in my depression symptoms?
Some individuals may experience improvements within hours or days of their first esketamine treatment, while others may need a few sessions before noticing significant changes.
